77. Growth hormone secreting pituitary adenoma
[
1 clinical trial,
1 drug（DrugBank:
1 drug),
2 target genes / 19 target pathways ]
Searched query = "Growth hormone secreting pituitary adenoma", "Pituitary growth hormone secretion hyperthyroidism"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1800017714 | 2019-01-01 | 20 August 2018 | The Effect and safety Assessment of Metformin Therapy in Growth Hormone-secreting Pituitary Adenoma (GH-PA) Patients who inoperable or incomplete control after surgery | The Effect and safety Assessment of Metformin Therapy in Growth Hormone-secreting Pituitary Adenoma (GH-PA) Patients who inoperable or incomplete control after surgery | Growth Hormone-secreting Pituitary Adenoma (GH-PA) | Bromocentine Group:bromocentine mesylate tablet, starting dose is 0.625-1.25mg/d and the weekly increase of 1.25mg/d until 10-15mg/d.;Bromocentine and Metformin Group:metformin hydrochloride enteric solution 0.5g three times a day added on the basis of bromocentine mesylate tablet;Gamma Knife Radiosurgery Group:Gamma Knife Radiosurgery;Gamma Knife Radiosurgery and Metformin Group:metformin hydrochloride enteric solution 0.5g three times a day added on the basis of gamma knife radiosurgery; | Department of Endocrinology, Second Affiliated Hospital of Army Medical University | Not Recruiting | 18 | 70 | Both | Bromocentine Group:10;Bromocentine and Metformin Group:10;Gamma Knife Radiosurgery Group:10;Gamma Knife Radiosurgery and Metformin Group:10; | New Treatment Measure Clinical Study | China |